ZIRA: A new prognostic biomarker of estrogen receptor- positive (ER plus ) breast cancers

被引：0
|
作者：
Vendrell, J. [1 ]
Nguyen, N. T. [1 ]
Gyorffy, B. [3 ]
Leon, S. [2 ]
Grisard, E. [1 ]
Bachelot, T. [2 ]
Treilleux, I. [2 ]
Cohen, P. A. [1 ]
机构：
[1] Univ Lyon 1, Ctr Rech Cancerol Lyon, F-69365 Lyon, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Hungarian Acad Sci, Res Lab Pediat & Nephrol, Budapest, Hungary
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)50569-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
649
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [41] Characterization of Estrogen Receptor Negative/Progesterone Receptor Positive/(ER-/PR plus ) Breast Cancer (BC)
    Shen, Tiansheng
    Brandwein-Gensler, Margaret
    Hameed, Omar
    Siegal, Gene
    Wei, Shi
    LABORATORY INVESTIGATION, 2015, 95 : 65A - 65A
  • [42] The Oncotype DX Assay (ODX) May Not Be Required for All Estrogen Receptor (ER) Positive Breast Cancers
    Shiffer, J. D.
    Obadia, B.
    Apple, S.
    Dadmanesh, F.
    Wolin, E.
    McAndrew, P.
    Bose, S.
    MODERN PATHOLOGY, 2010, 23 : 71A - 72A
  • [43] WHY ARE ESTROGEN-RECEPTOR-NEGATIVE BREAST CANCERS MORE AGGRESSIVE THAN THE ESTROGEN-RECEPTOR-POSITIVE BREAST CANCERS
    SHEIKH, MS
    GARCIA, M
    PUJOL, P
    FONTANA, JA
    ROCHEFORT, H
    INVASION & METASTASIS, 1994, 14 (1-6): : 329 - 336
  • [44] The Oncotype DX Assay (ODX) May Not Be Required for All Estrogen Receptor (ER) Positive Breast Cancers
    Shiffer, J. D.
    Obadia, B.
    Apple, S.
    Dadmanesh, F.
    Wolin, E.
    McAndrew, P.
    Bose, S.
    LABORATORY INVESTIGATION, 2010, 90 : 71A - 72A
  • [45] Estrogen receptor is a target of enzalutamide in ER plus breast cancer
    Wei, Lixuan
    Yu, Jia
    Gao, Huanyao
    Zhang, Huan
    Nguyen, Thanh
    Gu, Yayun
    Weinshilboum, Richard M.
    Ingle, James N.
    Wang, Liewei
    CANCER RESEARCH, 2022, 82 (04)
  • [46] Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
    Iwamoto, Takayuki
    Booser, Daniel
    Valero, Vicente
    Murray, James L.
    Koenig, Kimberly
    Esteva, Francisco J.
    Ueno, Naoto T.
    Zhang, Jie
    Shi, Weiwei
    Qi, Yuan
    Matsuoka, Junji
    Yang, Elliana J.
    Hortobagyi, Gabriel N.
    Hatzis, Christos
    Symmans, W. Fraser
    Pusztai, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (07) : 729 - 734
  • [47] The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
    Narbe, Ulrik
    Sjostrom, Martin
    Forsare, Carina
    Bendahl, Par-Ola
    Alkner, Sara
    Leeb-Lundberg, L. M. Fredrik
    Lovgren, Kristina
    Ryden, Lisa
    Ingvar, Christian
    Ferno, Marten
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 305 - 316
  • [48] The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
    Ulrik Narbe
    Martin Sjöström
    Carina Forsare
    Pär-Ola Bendahl
    Sara Alkner
    L. M. Fredrik Leeb-Lundberg
    Kristina Lövgren
    Lisa Rydén
    Christian Ingvar
    Mårten Fernö
    Breast Cancer Research and Treatment, 2019, 175 : 305 - 316
  • [49] MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER plus breast cancer
    Milevskiy, Michael J. G.
    Gujral, Udai
    Marques, Carolina Del Lama
    Stone, Andrew
    Northwood, Korinne
    Burke, Lez J.
    Gee, Julia M. W.
    Nephew, Kenneth
    Clark, Susan
    Brown, Melissa A.
    BRITISH JOURNAL OF CANCER, 2019, 120 (06) : 621 - 632
  • [50] CCNB1 is a prognostic biomarker for ER plus breast cancer
    Ding, Kun
    Li, Wenqing
    Zou, Zhiqiang
    Zou, Xianzhi
    Wang, Chengru
    MEDICAL HYPOTHESES, 2014, 83 (03) : 359 - 364
12345